Abstract：
Teratogenicity and hyperuricaemia are the main side effects of favipiravir, an antiviral drug recently found its use to treat mild to moderate coronavirus (COVID-19) infections. This study investigated the beneficial effect of herbal extracts like Picrorrhiza kurroa (PK) and Scutellaria baicalensis (SB) and their active chemical constituents (baicalin and baicalein) on favipiravir-induced hepatotoxicity in rats. The formulation combinations included favipiravir, favipiravir + PK extract, favipiravir + pure baicalin, favipiravir + pure baicalein, and favipiravir + SB extract designated as F1, F2, F3, F4 and F5 respectively that were administered to rats orally for 21 days. Favipiravir caused increased levels of SGOT, SGPT, ALP, total bilirubin, and uric acid and decreased liver weight which was alleviated when alloherbal formulation of favipiravir and baicalein combination and favipiravir and SB extract was used. This paper highlights an attractive proposition to ameliorate favipiravir-induced hepatotoxicity using hepatoprotective agents.
摘要：
致畸和高尿酸血症是favipiravir的主要副作用，一种抗病毒药物最近发现可用于治疗轻度至中度冠状病毒(COVID-19)感染。这项研究调查了中药提取物如苦根（PK）和黄芩（SB）及其活性化学成分（黄芩苷和黄芩素）对法比拉韦诱导的大鼠肝毒性的有益作用。制剂组合包括favipiravir，favipirravir+PK提取物，法比拉韦+纯黄芩苷,法比拉韦+纯黄芩素,和分别指定为F1、F2、F3、F4和F5的faviravir+SB提取物,将其口服给予大鼠21天。Favipiravir导致SGOT水平升高，SGPT,ALP,总胆红素,和尿酸和肝脏重量降低，当使用法哌韦和黄芩素组合以及法哌韦和SB提取物的异草药制剂时，可以减轻。本文强调了使用肝保护剂改善favipirravir诱导的肝毒性的有吸引力的主张。
